Moderna shares jump as intismeran autogene nears next test
Moderna said it will present three abstracts on intismeran autogene, its personalized mRNA cancer vaccine, ahead of its next major test.
Story updates
05:14:10 PM UTC
SquawkNews
What Happened? Shares of biotechnology company Moderna NASDAQ:MRNAjumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran autogene, alongside Merck's Keytruda in high-risk melanoma patients continued to drive mom…
Moderna stock nearly tripled in a single day last month after the drugmaker showed a personalized cancer vaccine is no longer just theoretical. Investors are about to learn what comes next. The company said Monday that three abstracts on intismeran autogene, the mRNA cancer vaccine, are set to be presented at the upcoming medical meeting.